title: RNA interference of hypoxia-inducible factor-1 alpha improves the effects of transcatheter arterial embolization in rat liver tumors.
abstract: Transcatheter arterial embolization (TAE) and transcatheter arterial chemoembolization are widely used palliative treatments for patients with nonsurgical hepatocellular carcinoma. TAE has been shown to increase levels of hypoxia-inducible factor-1 alpha (HIF-1α) in tumors. In this study, we investigated whether RNA interference (RNAi) of HIF-1α could improve the efficacy of TAE to treat HCC. Four treatment groups were assessed using a rat allograft model of HCC: RNAi of HIF-1α combined with TAE, RNAi of HIF-1α only, TAE only, and a control group. Rats were treated by TAE by retrograde placement of a microcatheter into the gastroduodenal artery. The results demonstrated that the RNAi of HIF-1α visibly reduced the expression of HIF-1α and vascular endothelial growth factor, suppressed tumor angiogenesis, and attenuated metastasis, which were all enhanced by TAE. The RNAi of HIF-1α synergized with TAE to significantly inhibit tumor growth. In conclusion, RNAi of HIF-1α augmented the therapeutic effects of TAE and diminished its undesirable effects.
authors.affiliation: Department of Radiology, Zhong Shan Hospital, Fudan University, No.180 Fenglin Road, Shanghai 200032, China.
authors.forename: ChengShi
authors.initials: C
authors.lastname: Chen
authors.forename: JianHua
authors.initials: J
authors.lastname: Wang
authors.forename: Rong
authors.initials: R
authors.lastname: Liu
authors.forename: Sheng
authors.initials: S
authors.lastname: Qian
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002404:Catheterization; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D051793:Hypoxia-Inducible Factor 1 / Q000235:genetics* / Q000378:metabolism; D007150:Immunohistochemistry; D008114:Liver Neoplasms, Experimental / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D034622:RNA Interference; D051381:Rats; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D047368:Tumor Burden / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D051793:Hypoxia-Inducible Factor 1; D042461:Vascular Endothelial Growth Factor A